In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Servier options rights to three of MacroGenics' DART compounds; deal ends

Executive Summary

Building on a relationship that began with a separate deal almost a year ago, Servier SA has once again optioned rights to early-stage projects from MacroGenics Inc. (therapies for autoimmune and infectious diseases and cancer). This time, the French pharmaco has its sights on three of MacroGenics’ preclinical anticancer DART (Dual-Affinity Re-Targeting) compounds.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Immuno-Oncology
    • Large Molecule
      • Antibodies
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies